Daily GLP-1 tablets are widening access to obesity treatment and boosting industry expectations.
Analysts now value the global market at up to $200bn by the early 2030s.
Novo Nordisk launched the first oral version of Wegovy in the US.
Early demand outpaced the original injection.
Patients say pills feel easier to manage and avoid weekly shots.
Lower storage needs and reduced prices also attract new users.
Rival Eli Lilly is preparing its own tablet, orforglipron.
More oral drugs from biotech firms are in development.
Broader insurance coverage in the US will further expand uptake.
Injections still produce greater weight loss.
They will likely remain the choice for people with severe obesity.
Pills are expected to draw those who are overweight or needle-averse.
High costs, side-effects and weight regain after stopping treatment remain key concerns.
Health systems are also assessing long-term cost-effectiveness.
With obesity rates rising worldwide, drugmakers see a vast untreated population.
The move from injections to tablets marks a decisive new stage in the competition for this market.
